Headquartered in Hampton, NJ Fiscal year ends December NASDAQ: CLDX celldex.com
Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for allergic, inflammatory, and autoimmune disorders. The company's pipeline centers on mast cell biology, with its lead candidate barzolvolimab — a humanized monoclonal antibody targeting the KIT receptor to deplete mast cells — in Phase 3 trials for chronic spontaneous urticaria and Phase 2/3 development for cold urticaria, symptomatic dermographism, and atopic dermatitis. Celldex is also developing CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP, currently in Phase 1 studies for asthma with planned expansion into allergic rhinitis and food allergy. The company generates minimal revenue from legacy manufacturing and research agreements and is pre-commercial, funding operations through equity offerings and its investment portfolio. Updated
Monday’s top analyst upgrades and downgrades included American Express, Capital One, Levi Strauss, Pinterest, Peloton, Synchrony and T-Mobile.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
Ambev, Renren, Celldex, and Yatra Online all posted new 52-week lows Friday.
Paul Ausick General Electric, Starbucks, General Dynamics, and Celldex all posted new 52-week lows Thursday.
Oracle, Starbucks, Helios and Matheson, and Celldex all posted new 52-week lows Wednesday.
Banco Bradesco, Gogo, Tesaro, and Celldex all posted new 52-week lows Wednesday.
J.C. Penney, Helios and Matheson, Celldex, and Spectra Energy Partners all posted new 52-week lows Tuesday.
MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday.
Celldex Therapeutics, Acacia Communications, Apricus Biosciences, and Ctrp.com all posted new 52-week lows Monday.
Paul Ausick Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study.
Chris Lange Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should…
The top analyst upgrades, downgrades and other research calls include American Airlines, Boeing, Cabot Oil & Gas, Pandora Media, Southern Co. and Vertex Pharmaceuticals.
Macy's, Tegna, Celldex, and DryShips posted new 52-week lows Tuesday.
Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO). Unfortunately, the move was to the downside.
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for allergic, inflammatory, and autoimmune disorders.
The Wall Street consensus 12-month price target for CLDX is $63.07.
